Which has higher earnings & valuation, AEON or ELTX?

Elicio Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AEON Biopharma N/A N/A -$36.63M -$4.42 N/A Elicio Therapeutics N/A N/A -$39.57M -$2.17 N/A

Is AEON or ELTX more profitable?

AEON Biopharma's return on equity of 0.00% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets AEON Biopharma N/A N/A -994.63% Elicio Therapeutics N/A -1,266.43% -139.94%

Do analysts recommend AEON or APLM?

AEON Biopharma presently has a consensus price target of $1.33, indicating a potential upside of 408.91%. Given AEON Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe AEON Biopharma is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AEON Biopharma 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, AEON or APLM?

Apollomics has higher revenue and earnings than AEON Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AEON Biopharma N/A N/A -$36.63M -$4.42 N/A Apollomics $8.50M 7.85 -$10.94M N/A N/A

Is AEON or APLM more profitable?

Company Net Margins Return on Equity Return on Assets AEON Biopharma N/A N/A -994.63% Apollomics N/A N/A N/A

Which has better valuation & earnings, AEON or TVGN?

Tevogen Bio is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AEON Biopharma N/A N/A -$36.63M -$4.42 N/A Tevogen Bio N/A N/A -$26.27M -$4.63 N/A

Is AEON or TVGN more profitable?

Company Net Margins Return on Equity Return on Assets AEON Biopharma N/A N/A -994.63% Tevogen Bio N/A N/A -468.32%

Do analysts rate AEON or BKHA?

AEON Biopharma presently has a consensus target price of $1.33, suggesting a potential upside of 408.91%. Given AEON Biopharma's stronger consensus rating and higher possible upside, equities analysts clearly believe AEON Biopharma is more favorable than Black Hawk Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AEON Biopharma 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, AEON or BKHA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AEON Biopharma N/A N/A -$36.63M -$4.42 N/A Black Hawk Acquisition N/A N/A N/A N/A N/A

Is AEON or BKHA more profitable?

Company Net Margins Return on Equity Return on Assets AEON Biopharma N/A N/A -994.63% Black Hawk Acquisition N/A N/A N/A

Which has better earnings & valuation, AEON or TIL?

Instil Bio is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AEON Biopharma N/A N/A -$36.63M -$4.42 N/A Instil Bio N/A N/A -$71.37M -$4.47 N/A

Is AEON or TIL more profitable?

AEON Biopharma's return on equity of 0.00% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets AEON Biopharma N/A N/A -994.63% Instil Bio N/A -26.78% -14.89%

AEON Biopharma (AEON) Competitors

$0.26 -0.01 (-2.24%)

As of 11:49 AM Eastern

Compare

AEON vs. ELTX, APLM, TVGN, BKHA, and TIL

Should you buy AEON Biopharma stock or one of its competitors? AEON Biopharma's main competitors and comparable companies include Elicio Therapeutics (ELTX), Apollomics (APLM), Tevogen Bio (TVGN), Black Hawk Acquisition (BKHA), and Instil Bio (TIL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AEON Biopharma compare to Elicio Therapeutics?

AEON Biopharma (NASDAQ:AEON) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by company insiders. Comparatively, 50.9% of Elicio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Elicio Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A

AEON Biopharma currently has a consensus target price of $1.33, indicating a potential upside of 408.91%. Elicio Therapeutics has a consensus target price of $15.00, indicating a potential upside of 725.08%. Given Elicio Therapeutics' higher probable upside, analysts clearly believe Elicio Therapeutics is more favorable than AEON Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

AEON Biopharma has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market.

In the previous week, Elicio Therapeutics had 5 more articles in the media than AEON Biopharma. MarketBeat recorded 5 mentions for Elicio Therapeutics and 0 mentions for AEON Biopharma. Elicio Therapeutics' average media sentiment score of 0.34 beat AEON Biopharma's score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
AEON Biopharma	Neutral
Elicio Therapeutics	Neutral

AEON Biopharma's return on equity of 0.00% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Elicio Therapeutics	N/A	-1,266.43%	-139.94%

Summary

Elicio Therapeutics beats AEON Biopharma on 8 of the 12 factors compared between the two stocks.

How does AEON Biopharma compare to Apollomics?

AEON Biopharma (NASDAQ:AEON) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

AEON Biopharma has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market.

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Apollomics	N/A	N/A	N/A

AEON Biopharma presently has a consensus price target of $1.33, indicating a potential upside of 408.91%. Given AEON Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe AEON Biopharma is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics has higher revenue and earnings than AEON Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A
Apollomics	$8.50M	7.85	-$10.94M	N/A	N/A

In the previous week, AEON Biopharma's average media sentiment score of 0.00 equaled Apollomics'average media sentiment score.

Company	Overall Sentiment
AEON Biopharma	Neutral
Apollomics	Neutral

Summary

AEON Biopharma beats Apollomics on 5 of the 9 factors compared between the two stocks.

How does AEON Biopharma compare to Tevogen Bio?

AEON Biopharma (NASDAQ:AEON) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

AEON Biopharma has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Tevogen Bio	N/A	N/A	-468.32%

Tevogen Bio is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A

AEON Biopharma currently has a consensus target price of $1.33, suggesting a potential upside of 408.91%. Tevogen Bio has a consensus target price of $100.00, suggesting a potential upside of 1,224.15%. Given Tevogen Bio's higher probable upside, analysts plainly believe Tevogen Bio is more favorable than AEON Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

22.8% of AEON Biopharma shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by company insiders. Comparatively, 65.6% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Tevogen Bio had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 1 mentions for Tevogen Bio and 0 mentions for AEON Biopharma. AEON Biopharma's average media sentiment score of 0.00 equaled Tevogen Bio'saverage media sentiment score.

Company	Overall Sentiment
AEON Biopharma	Neutral
Tevogen Bio	Neutral

Summary

AEON Biopharma beats Tevogen Bio on 6 of the 11 factors compared between the two stocks.

How does AEON Biopharma compare to Black Hawk Acquisition?

AEON Biopharma (NASDAQ:AEON) and Black Hawk Acquisition (NASDAQ:BKHA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Black Hawk Acquisition	N/A	N/A	N/A

AEON Biopharma presently has a consensus target price of $1.33, suggesting a potential upside of 408.91%. Given AEON Biopharma's stronger consensus rating and higher possible upside, equities analysts clearly believe AEON Biopharma is more favorable than Black Hawk Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

22.8% of AEON Biopharma shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

AEON Biopharma has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Black Hawk Acquisition has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market.

In the previous week, Black Hawk Acquisition had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 1 mentions for Black Hawk Acquisition and 0 mentions for AEON Biopharma. Black Hawk Acquisition's average media sentiment score of 0.35 beat AEON Biopharma's score of 0.00 indicating that Black Hawk Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
AEON Biopharma	Neutral
Black Hawk Acquisition	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

AEON Biopharma beats Black Hawk Acquisition on 6 of the 9 factors compared between the two stocks.

How does AEON Biopharma compare to Instil Bio?

AEON Biopharma (NASDAQ:AEON) and Instil Bio (NASDAQ:TIL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

In the previous week, AEON Biopharma's average media sentiment score of 0.00 equaled Instil Bio'saverage media sentiment score.

Company	Overall Sentiment
AEON Biopharma	Neutral
Instil Bio	Neutral

AEON Biopharma has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market.

AEON Biopharma currently has a consensus price target of $1.33, indicating a potential upside of 408.91%. Instil Bio has a consensus price target of $7.00, indicating a potential downside of 1.69%. Given AEON Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe AEON Biopharma is more favorable than Instil Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

AEON Biopharma's return on equity of 0.00% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Instil Bio	N/A	-26.78%	-14.89%

Instil Bio is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by insiders. Comparatively, 47.0% of Instil Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

AEON Biopharma beats Instil Bio on 7 of the 11 factors compared between the two stocks.

Get AEON Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AEON vs. The Competition

Export

Metric	AEON Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.07M	$3.91B	$7.27B	$13.03B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	1.46	14.13	274.95	25.63
Price / Sales	N/A	1,446.16	669.16	97.27
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	-0.06	15.01	10.32	6.26
Net Income	-$36.63M	-$22.82M	$3.49B	$360.12M
7 Day Performance	6.37%	-2.72%	-1.33%	-0.42%
1 Month Performance	32.73%	-7.12%	-3.71%	-3.75%
1 Year Performance	-66.41%	29.24%	14.41%	4.84%

AEON Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AEON AEON Biopharma	3.9353 of 5 stars	$0.26 -2.2%	$1.33 +416.8%	-66.6%	$12.92M	N/A	1.44	8
ELTX Elicio Therapeutics	2.5314 of 5 stars	$1.99 -0.5%	$19.75 +892.5%	-83.2%	$52.30M	N/A	N/A	N/A	News Coverage Positive News Analyst Forecast
APLM Apollomics	1.1584 of 5 stars	$23.13 -0.2%	N/A	+25.1%	$50.80M	$8.50M	N/A	45	Gap Down
TVGN Tevogen Bio	1.0387 of 5 stars	$7.75 +3.2%	$100.00 +1,190.3%	-80.6%	$50.46M	N/A	N/A	3	News Coverage Gap Down
BKHA Black Hawk Acquisition	N/A	$11.93 -0.5%	N/A	+9.0%	$49.49M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AEON) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AEON Biopharma (AEON) Competitors

AEON vs. ELTX, APLM, TVGN, BKHA, and TIL

How does AEON Biopharma compare to Elicio Therapeutics?

Summary

How does AEON Biopharma compare to Apollomics?

Summary

How does AEON Biopharma compare to Tevogen Bio?

Summary

How does AEON Biopharma compare to Black Hawk Acquisition?

Summary

How does AEON Biopharma compare to Instil Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON vs. The Competition

AEON Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AEON Biopharma (AEON) Competitors

AEON vs. ELTX, APLM, TVGN, BKHA, and TIL

How does AEON Biopharma compare to Elicio Therapeutics?

Do insiders & institutionals hold more shares of AEON or ELTX?

Which has higher earnings & valuation, AEON or ELTX?

Do analysts rate AEON or ELTX?

Which has more volatility & risk, AEON or ELTX?

Does the media refer more to AEON or ELTX?

Is AEON or ELTX more profitable?

Summary

How does AEON Biopharma compare to Apollomics?

Which has more volatility and risk, AEON or APLM?

Do institutionals & insiders hold more shares of AEON or APLM?

Is AEON or APLM more profitable?

Do analysts recommend AEON or APLM?

Which has stronger earnings & valuation, AEON or APLM?

Does the media refer more to AEON or APLM?

Summary

How does AEON Biopharma compare to Tevogen Bio?

Which has more risk and volatility, AEON or TVGN?

Is AEON or TVGN more profitable?

Which has better valuation & earnings, AEON or TVGN?

Do analysts prefer AEON or TVGN?

Do insiders and institutionals have more ownership in AEON or TVGN?

Does the media favor AEON or TVGN?

Summary

How does AEON Biopharma compare to Black Hawk Acquisition?

Is AEON or BKHA more profitable?

Do analysts rate AEON or BKHA?

Do insiders & institutionals have more ownership in AEON or BKHA?

Which has more risk and volatility, AEON or BKHA?

Does the media favor AEON or BKHA?

Which has higher valuation and earnings, AEON or BKHA?

Summary

How does AEON Biopharma compare to Instil Bio?

Does the media refer more to AEON or TIL?

Which has more volatility & risk, AEON or TIL?

Do analysts prefer AEON or TIL?

Is AEON or TIL more profitable?

Which has better earnings & valuation, AEON or TIL?

Do institutionals and insiders have more ownership in AEON or TIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON vs. The Competition

AEON Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools